8-KEarnings & ResultsExhibits & Filings

DEXCOM INC 8-K Report, Financial Results (Nov 1, 2016)

Filed November 1, 2016For Securities:DXCM

Summary

DexCom, Inc. (DXCM) filed an 8-K on November 1, 2016, to report its financial results for the third quarter ended September 30, 2016. The filing primarily references a press release (Exhibit 99.01) which contains the detailed financial and operational information. Investors should note that this information is furnished and not deemed "filed" with the SEC, meaning it doesn't carry the same liability implications as fully filed information. The key takeaway for investors is to review the accompanying press release for comprehensive details on the company's performance during the period.

Key Highlights

  • 1DexCom announced its third-quarter 2016 financial results on November 1, 2016.
  • 2The results were disclosed via a press release furnished as Exhibit 99.01 to the 8-K filing.
  • 3The filing covers the three-month period ending September 30, 2016.
  • 4This 8-K is primarily a notification of the press release containing financial results.
  • 5Information furnished under Item 2.02 is not considered 'filed' for Section 18 liability purposes.
  • 6Investors must refer to Exhibit 99.01 for the actual financial figures and operational details.

Frequently Asked Questions

The actual financial results and other relevant information for the third quarter ended September 30, 2016, are contained within the press release furnished as Exhibit 99.01 to this 8-K filing.

No, the information in this Item 2.02, including the press release, is furnished, not 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934. This means it does not carry the same legal liabilities.

This 8-K filing serves as an official notification to the market that DexCom has released its quarterly financial results. The core financial details are in the accompanying press release.

The filing itself does not explicitly state updated guidance. Investors would need to consult the furnished press release (Exhibit 99.01) for any forward-looking statements or guidance provided by DexCom for the period.